Literature DB >> 10604172

[Oral antibiotic therapy in the adult bacterial osteomyelitis: results after two years of follow-up].

M Javaloyas de Morlius1, M Monreal Portella.   

Abstract

BACKGROUND: Oral antibiotic therapy achieves clinical and bacteriological cure of the adult bacterial osteomyelitis associated or not to orthopedic implant. PATIENTS AND METHODS: We carried out a prospective study, with follow-up at 24 months, of patients with adult bacterial osteomyelitis, that were initially treated with parenteral antibiotic therapy for a week, followed with oral antibiotic therapy during 2 to 6 months, depending on the absence or presence or orthopedic implant, respectively.
RESULTS: 37 patients presented 44 episodes of adult bacterial osteomyelitis, 34 of them in presence of orthopedic implant. The most frequent causative microorganism was S. aureus (44%), followed by coagulase-negative Staphylococcus (29%). The oral antibiotic therapy most frequently employed was the combination cotrimoxazole-rifampin, followed by ciprofloxacin-rifampin. The clinical and bacteriologic cure were 85%, 82% in the group with orthopedic implant. 82% required surgical intervention.
CONCLUSIONS: The oral antibiotic therapy, preceded by a short parenteral therapy, can get high rates of clinical and bacteriological cure in the adult's bacterial osteomyelitis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10604172

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  3 in total

Review 1.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

2.  A modified staging system for chronic osteomyelitis.

Authors:  Leonard Charles Marais; Nando Ferreira; Colleen Aldous; Benn Sartorius; Theo Le Roux
Journal:  J Orthop       Date:  2015-06-12

3.  Staphylococcus aureus and Escherichia hermanii in diabetes patient.

Authors:  Gabriel Adrian Popescu; Ioana Daha; Cristina Popescu; Elena Mitache
Journal:  Emerg Infect Dis       Date:  2004-07       Impact factor: 6.883

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.